BDMD — H1 2026 Financial Report Analysis

A first-half profit made entirely by a new licensing deal, while the core device business shrank

Baird Medical, a Guangzhou-based maker of microwave ablation (MWA) systems used mainly to treat thyroid nodules, reported a first half of 2026 that looks like a turnaround: revenue up 24.6% to $9.9 million and a small net profit of $13,499, against an $11.4 million loss a year earlier. Underneath, the picture is different. All of the revenue growth came from $4.8 million of technology licensing fees, a business launched this half in which Baird lets overseas companies use its ablation technology outside China. The products Baird actually makes and sells, ablation needles and machines, brought in 37.8% less than a year ago. The swing to profit also depended on spending cuts: research and development fell by about four-fifths, and share-based pay fell.

At a glance

• $4.8 million of licensing revenue (48% of the half's sales), up from nothing. Without it, revenue would have fallen 35.7%, to about $5.1 million.
• Device sales: $4.95 million, down from $7.96 million (-37.8%). Needle sales, the repeat-purchase part of the business, fell 42.7%.
• $0.14 million of cash at June 30, against $14.1 million of bank loans due within a year. Since the period ended, the company has borrowed through a convertible note that can be repaid in new shares. Each payment in shares dilutes existing holders, and the lower the share price, the more shares it takes.

The numbers

n/m = not meaningful (a change from a loss to a profit has no sensible percentage).

Gross margin is the share of revenue left after the direct cost of the products sold. Operating margin is what remains after running the business as well (sales staff, administration, R&D), before interest and tax.

Small as it is, the profit does not reach ordinary shareholders: EPS is still slightly negative. The filing deducts a $101,500 dividend owed to preferred shareholders from the $35,405 attributable profit, which leaves a $66,095 loss for ordinary shares, or -$0.002 per share.

Takeaway: Baird's first profitable half rests on a single new source of revenue: $4.8 million of licensing fees. These were recognised in full when licensees signed off on the technology handover, on credit terms of up to 365 days, and under licences the filing says are "granted on an annual basis". Strip them out and the half was an operating loss of roughly $4 million, on a device business whose sales in China fell by half. Two things will decide whether this is a turnaround: whether the licensing fees come back next year, and whether they are actually paid in cash.

Where the revenue came from

The change is clearest by customer location:

Sales in China, historically almost the whole business, fell 51%. The filing says each licensee gets an exclusive right to use the technology "in specified territories outside the PRC (including Europe, Brazil, the UK, or other defined regions)". Most of the Hong Kong and US jump is therefore licensing and overseas device sales, not a recovery at home. Revenue is also now concentrated: two customers made up 28.2% and 25.4% of the half's revenue, compared with 14.8% and 12.3% a year earlier.

By product, needles (the disposable part used in each procedure) fell to $3.75 million from $6.54 million. The ablation machines themselves fell to $1.20 million from $1.42 million. Management's explanation:

• Sales through distributors fell from $5.3 million to $4.5 million. About $0.6 million of the drop came from lower prices and $0.2 million from lower volume. Machine units rose but prices fell more.
• Direct sales to hospitals collapsed from $2.7 million to $0.5 million. Most of this was volume (about $1.9 million), with lower prices on both needles and machines accounting for the rest.

The filing does not say why Chinese hospital volumes fell so sharply.

Why costs fell so much

Total operating expenses fell by $9.2 million, which is most of the $11.3 million profit swing. The cuts were mostly in two lines that do not reflect day-to-day selling:

• R&D: $1.39 million, down from $7.18 million (-80.6%). Management attributes this to lower spending on FDA certification fees, CE marking (the EU's medical device approval), an endoscopic ultrasound system and AI ablation systems. It describes the drop as "the timing and nature of research and development project milestones, rather than a reduction in the Company's commitment to innovation". If that is true, the spending should come back.
• General and administrative: $3.40 million, down from $8.68 million. Almost all of this is share-based compensation (pay in shares rather than cash), which fell from $6.3 million to $0.5 million within this line.
• Selling and marketing rose to $2.98 million from $1.13 million. This was mostly $1.9 million of new share-based pay, plus $0.3 million more in staff costs for US sales staff.

What the headline numbers hide

• The licensing fees appear to carry almost no cost, and that is the whole profit. Cost of revenue fell 9.3%, to $1.29 million, and the filing explains the decline entirely by lower device sales. No separate licensing cost appears, so the $4.8 million seems to have gone almost straight to operating income. On the half's own figures, operating income of $0.85 million minus $4.8 million of licensing leaves an operating loss of about $4.0 million for the device business. This is our own subtraction, and it assumes licensing had near-zero direct cost, which the filing implies but does not state.
• Whether the licensing revenue repeats is unclear. The fee is recognised all at once, "upon when the customer accepted and signed the List of Technical Deliverables". The filing says contracts run longer than a year but the licence "is granted on an annual basis". It also says there are "no material unsatisfied" obligations under these contracts at June 30. In other words, none of the future licensing revenue is booked yet. The next half could show $4.8 million again, or nothing.
• Receivables are large and ageing badly. Receivables are money customers owe for sales already booked. Net of the provision for bad debts they reached $44.4 million, about 4.5 times the half's revenue. Of the $50.2 million gross balance, $31.8 million is more than a year past its due date, up from $19.9 million at December. For the first time, management moved $13.7 million into "non-current", meaning it does not expect to collect that within a year. The bad-debt allowance covers only $5.8 million (11.6% of gross). Licensees were given 365-day credit terms, so part of this half's licensing revenue may also sit in receivables. The filing does not say how much of the $4.8 million has been paid.
• Operating cash flow was positive, though the cash came from other places than profit. The $2.46 million inflow came from adding back $2.4 million of share-based pay and $0.9 million of new bad-debt provisions, plus a $1.6 million rise in customer prepayments (contract liabilities rose to $2.4 million from $0.8 million). Against that, prepayments to suppliers rose $2.2 million and receivables rose $1.4 million.
• Prepayments are growing while R&D spending shrinks. Money paid in advance to suppliers, mostly R&D contractors, totals $20.5 million ($12.8 million current, $7.7 million non-current), up from $17.7 million at December. These are expensed as the contractors report progress. A rising prepaid balance alongside an 81% fall in R&D expense means a lot of paid-for work has not yet reached the income statement.
• Tax took almost all the pre-tax profit. Pre-tax income of $0.57 million carried a $0.56 million tax charge. Hong Kong (+$1.35 million) and US (+$0.21 million) operations made taxable profits, while the PRC operations lost $0.99 million, and the filing gives no sign that this loss reduced the tax bill.
• A one-off cleared: a 2024 regulatory penalty of about $0.6 million, over a two-month lapse in the manufacturing licence in 2021, was paid in full in January 2026. This released $0.4 million of cash that had been frozen.

Balance sheet and funding: the real pressure point

At June 30 Baird had $0.14 million of cash plus $0.15 million restricted. Debts due within a year were $10.76 million of short-term bank loans and $3.32 million of long-term loans falling due. It also owed $3.54 million to a related party (Betters Medical Investment Holdings) and had $5.15 million of listing expenses still unpaid. Working capital (current assets minus current liabilities) is positive at $10.2 million, but $30.7 million of the current assets are receivables. The company says it fully repaid and redrew $7.7 million of bank loans during the half, so it relies on banks to keep renewing them.

Management concluded there is no substantial doubt about the company's ability to keep operating as a going concern. It relies partly on a letter from Chairwoman and CEO Haimei Wu committing up to $2.0 million of support, backed by her properties, and on Betters Medical agreeing not to demand repayment for 12 months.

What has happened since June 30:

• In July a US subsidiary borrowed $525,000, due by January 26, 2027.
• In late September the company sold a $4.35 million, 12-month convertible note to an institutional investor and received about $4 million. It carries no interest unless the company defaults. The holder can convert it into shares at the lower of $0.9842 or 92% of the lowest daily average trading price over the seven trading days before converting. Because that price falls with the stock, a lower share price means more new shares. The stock closed at $0.79 the day before closing. At around that level, converting the whole note would create roughly 5.5–6 million new shares, about 17–19% of the 32.0 million outstanding (our arithmetic from the filing's terms). A further $3.68 million tranche is available only if the stock closes above $1.00, among other conditions.

The share count has already risen. The weighted-average number of shares grew 18.7% year on year, to 31.3 million.

Outlook

The filing gives no revenue or profit guidance. Management lists "pursuing cooperation opportunities", lower fixed labour costs and "potential financing" as its plan. Our read for the second half:

• Licensing renewals or new licensees. Without another licensing deal, the device business on its own has been running at an operating loss.
• Cash collection. The $4.8 million of licensing receivables, and any progress on the $31.8 million of receivables more than a year overdue, matter more than reported profit for a company with $0.14 million in the bank.
• China device volumes. Direct-to-hospital sales fell by four-fifths and needle volumes declined. A rebound would show up in PRC revenue, which was $3.26 million this half.
• Conversions of the note. Each conversion adds shares. How many depends on where the stock trades.
• R&D coming back. If R&D returns to 2025 levels, as management's "timing" explanation implies, it would cost several million dollars per half.

The next scheduled report is the FY2026 annual report on Form 20-F. Last year's was filed on April 24, 2026, so the next is likely around late April 2027. Baird is a foreign private issuer and does not file quarterly reports.

Source: Baird Medical Form 6-K furnished September 30, 2026: Exhibit 99.1 (unaudited interim condensed consolidated financial statements for the six months ended June 30, 2026) and Exhibit 99.2 (MD&A); convertible note terms from the Form 6-K furnished the same day.